Estradiol valerate/norethisterone enantate (EV/NETE), sold under the brand name Mesigyna among others, is a form of combined injectable birth control which is used to prevent pregnancy in women.    It contains estradiol valerate (EV), an estrogen, and norethisterone enantate (NETE), a progestin.    The medication is given once a month by injection into muscle.    EV/NETE is approved for use in at least 36 countries, and is the most widely used combined injectable contraceptive.   It is available widely throughout Latin America, in a few Asian and African countries, and in Turkey.    EV/NETE is used as a combined injectable contraceptive to prevent pregnancy in women.    It is given by intramuscular injection once a month.    EV/NETE is available in the form of an oil solution containing 5 mg estradiol valerate (EV) and 50 mg norethisterone enantate (NETE).     EV/NETE, along with estradiol cypionate/medroxyprogesterone acetate (EC/MPA; code name HRP-112), was developed by the World Health Organization.   Both EV/NETE and EC/MPA became available in 1993.  EV/NETE is also known by its former developmental code name HRP-102.  EV/NETE has been marketed under a variety of brand names including Chinese Injectable No. 3, Efectimes, Ginediol, Mesigyna, Mesilar, Meslart, Mesocept, Mesygest, Nofertyl, Nofertyl Lafrancol, Noregyna, Norestrin, Norifam, Norigynon, Nostidyn, Sexseg, and Solouna.          EV/NETE has been marketed in at least 36 countries, including Argentina, the Bahamas, Barbados, Bolivia, Brazil, Chile, Colombia, Costa Rica, the Dominican Republic, Ecuador, Egypt, El Salvador, Ghana, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Kenya, Mexico, Nicaragua, Panama, Paraguay, Peru, St. Lucia, Turkey, Uruguay, Venezuela, and Zimbabwe.          At least 15 of the countries in which EV/NETE is registered are Caribbean states.  EV/NETE is the most widely used combined injectable contraceptive.    